For the quarter ending 2026-03-31, PHAT made $58,301K in revenue. -$30,369K in net income. Net profit margin of -52.09%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue, net | 58,301 | 57,584 | 49,504 | 39,503 |
| Cost of revenue | 11,996 | 7,647 | 6,190 | 5,038 |
| Gross profit | 46,305 | 49,937 | 43,314 | 34,465 |
| Research and development | 7,771 | 7,493 | 7,027 | 9,076 |
| Selling, general and administrative | 54,011 | 48,372 | 51,558 | 85,313 |
| Total operating expenses | 61,782 | 55,865 | 58,585 | 94,389 |
| Loss from operations | -15,477 | -5,928 | -15,271 | -59,924 |
| Interest income | 1,736 | 1,204 | 1,413 | 1,787 |
| Interest expense | 15,797 | 16,418 | 16,108 | 17,518 |
| Other expense, net | -831 | -6 | -7 | -155 |
| Total other expense | -14,892 | -15,220 | -14,702 | -15,886 |
| Net loss and comprehensive loss | -30,369 | -21,148 | -29,973 | -75,810 |
| Basic EPS | -0.37 | -0.286 | -0.41 | -1.05 |
| Diluted EPS | -0.37 | -0.286 | -0.41 | -1.05 |
| Basic Average Shares | 82,050,618 | 73,843,007 | 73,396,435 | 72,466,203 |
| Diluted Average Shares | 82,050,618 | 73,843,007 | 73,396,435 | 72,466,203 |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)